Google and existing investor Novo contributed to a series G2 round valuing the precision medicine developer at $8.1bn post-money.
US-based precision therapeutics developer Tempus raised $200m yesterday in a series G2 round featuring internet technology provider Google and pharmaceutical firm Novo, at an $8.1bn post-money valuation.
The corporates joined investment management firms Baillie Gifford and Franklin Templeton in the round along with funds and accounts managed by investment manager T. Rowe Price.
Tempus is applying artificial intelligence to large volumes of clinical and molecular data to develop precision medicine products for cancer, infectious and neurological diseases. The capital will…
